期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 27, 期 45, 页码 7771-7783出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i45.7771
关键词
Liver transplantation; Chronic rejection; Immunosuppression; T cell-mediated rejection; Antibody-mediated rejection; Donor-specific antibody; Re-transplantation; Graft loss; Complications; Outcomes
Chronic rejection (CR) is a significant cause of graft injury after liver transplantation, potentially leading to damage to intrahepatic vessels and bile ducts, and even necessitating re-transplantation. Early detection, identification of non-invasive biomarkers, and tailored management of immunosuppression are crucial for the treatment of CR.
Chronic rejection (CR) of liver allografts causes damage to intrahepatic vessels and bile ducts and may lead to graft failure after liver transplantation. Although its prevalence has declined steadily with the introduction of potent immunosuppressive therapy, CR still represents an important cause of graft injury, which might be irreversible, leading to graft loss requiring re-transplantation. To date, we still do not fully appreciate the mechanisms underlying this process. In addition to T cell-mediated CR, which was initially the only recognized type of CR, recently a new form of liver allograft CR, antibody-mediated CR, has been identified. This has indeed opened an era of thriving research and renewed interest in the field. Liver biopsy is needed for a definitive diagnosis of CR, but current research is aiming to identify new non-invasive tools for predicting patients at risk for CR after liver transplantation. Moreover, the minimization or withdrawal of immunosuppressive therapy might influence the establishment of subclinical CR-related injury, which should not be disregarded. Therapies for CR may only be effective in the early phases, and a tailored management of the immunosuppression regimen is essential for preventing irreversible liver damage. Herein, we provide an overview of the current knowledge and research on CR, focusing on early detection, identification of non-invasive biomarkers, immunosuppressive management, re-transplantation and future perspectives of CR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据